Monoclonal Antibody SC104 and Derivative Thereof Specifically Binding to a Sialyltetraosyl Carbohydrate as a Potential Anti-Tumor Therapeutic Agent
AssigneeCephalon Australia Pty Ltd
InventorsLinda Gillian Durrant, Tina Parsons
Life of this patent
Estimating the term…
Abstract
The present invention provides an isolated specific binding member capable of binding a sialyltetraosyl carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.
Claims31
An antibody binding domain which binds Colo205 and directly induces cell death without the need for immune effector cells, wherein the antibody binding domain comprises CDR1, CDR2 and CDR3 and wherein the sequence of CDR1 of the antibody binding domain is amino acids 44 to 54 or 49 to 54 of SEQ ID NO:
- 23.
An antibody binding domain which binds Colo205 and directly induces cell death without the need for immune effector cells, wherein the antibody binding domain comprises CDR1, CDR2 and CDR3 and wherein the sequence of CDR1 of the antibody binding domain is amino acids 46 to 55 of SEQ ID NO:
- 27.
An antibody binding domain which binds Colo205 and directly induces cell death without the need for immune effector cells, wherein the antibody binding domain comprises a heavy and a light chain wherein both the heavy and light chains comprise CDR1, CDR2 and CDR3 sequences and wherein the sequence of CDR1 of the heavy chain is amino acids 44 to 54 or 49 to 54 of SEQ ID NO:
- 23 and the sequence of CDR1 of the light chain is amino acids 46 to 55 of SEQ ID NO:
- 27.
Dependencies are inferred from the claim text.